KMG-732
KMG-732 is a dual-target inhibitor that targets GAK and β-tubulin, with Kd values of 12.0 nM and 19.3 μM, respectively. KMG-732 exhibits broad-spectrum antiproliferative activity in various human cancer cell lines and directly binds to purified tubulin in vitro. KMG-732 reduces the phosphorylation level of AP2M1, induces G2/M phase cell cycle arrest, disrupts the microtubule network, and inhibits cancer cell migration and invasion. KMG-732 shows significant antitumor activity in organoid and in vivo xenograft models. KMG-732 can be used for cancer research.
For research use only. We do not sell to patients.
- Formula: C23H17N7
- Molecular Weight:391.43
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| HepG2 | GI50 |
14.18 nM
|
KMG-732 inhibits the proliferation of HepG2 cells.
KMG-732 inhibits the proliferation of HepG2 cells.
|
42298883 |
| DLD-1 | GI50 |
16.62 nM
|
KMG-732 inhibits the proliferation of DLD-1 cells.
KMG-732 inhibits the proliferation of DLD-1 cells.
|
42298883 |
| HCT-116 | GI50 |
20.15 nM
|
KMG-732 inhibits the proliferation of HCT-116 cells.
KMG-732 inhibits the proliferation of HCT-116 cells.
|
42298883 |
| A549 | GI50 |
8.54 nM
|
KMG-732 inhibits the proliferation of A549 cells.
KMG-732 inhibits the proliferation of A549 cells.
|
42298883 |
| NCI-H522 | GI50 |
9.37 nM
|
KMG-732 inhibits the proliferation of NCI-H522 cells.
KMG-732 inhibits the proliferation of NCI-H522 cells.
|
42298883 |
| MDA-MB-231 | GI50 |
111.17 nM
|
KMG-732 inhibits the proliferation of MDA-MB-231 cells.
KMG-732 inhibits the proliferation of MDA-MB-231 cells.
|
42298883 |
| MIA PaCa-2 | GI50 |
2.97 nM
|
KMG-732 inhibits the proliferation of MIA PaCa-2 cells.
KMG-732 inhibits the proliferation of MIA PaCa-2 cells.
|
42298883 |
| BXPC-3 | GI50 |
16.46 nM
|
|
42298883 |
| SK-HEP1 | GI50 |
12.67 nM
|
|
42298883 |
| MCF7 | GI50 |
10.43 nM
|
|
42298883 |
In Vitro
KMG-732 (10 μM; 90 min) potently inhibits the polymerization of purified tubulin in vitro, with a Vmax of 13.95 mO.D./min[1].
KMG-732 (0.78-12.5 μM; 300 sec) exhibits binding affinity for purified tubulin in vitro, with a Kd value of 19.3 μM[1].
KMG-732 (1000 nM; 1 h) binds selectively and potently to purified GAK kinase in vitro with a Kd of 12.0 nM, while exhibiting extremely weak binding affinity toward most other tested kinases[1].
KMG-732 potently inhibits the activity of purified GAK kinase in vitro, with an IC50 of 73 nM[1].
KMG-732 (serial concentrations; 72 h) exhibits broad-spectrum antiproliferative activity against various human cancer cell lines in vitro: the GI50 values against pancreatic cancer Mia-paca2, KP2, and BxPC3 cells are 2.97, 10.84, and 16.46 nM, respectively; the GI50 values against colorectal cancer HCT116 and DLD-1 cells are 20.15 and 16.62 nM, respectively; the GI50 values against lung cancer A549 and H522 cells are 8.54 and 9.37 nM, respectively; the GI50 values against liver cancer SK-HEP-1 and HepG2 cells are 12.67 and 14.18 nM, respectively; the GI50 values against breast cancer MCF7 and MDA-MB-231 cells are 10.43 and 111.17 nM, respectively[1].
KMG-732 (0.1 μM; 1-16 h) completely disrupts the microtubule network in HCT116 colorectal cancer cells, which is characterized by perinuclear aggregation of tubulin and disappearance of cytoplasmic filamentous structures; it also induces the translocation of α-tubulin to the depolymerized (soluble) fraction, confirming its microtubule-destabilizing activity[1].
KMG-732 (1 μM; 6 h) reduces the levels of acetylated and detyrosinated α-tubulin (markers of stable microtubules) in HCT116 colorectal cancer cells within 6 hours of treatment[1].
KMG-732 (0.1-10 μM; 4 h pre-incubation plus 2 h EBI treatment) competes with the colchicine-site probe EBI for binding to β-tubulin in HCT116 colorectal cancer cells[1].
KMG-732 (10-100 nM) induces changes in the levels of mitotic regulatory proteins in HCT116 colorectal cancer cells (decreased Wee1 expression, increased Aurora A, Aurora B and Cyclin B1 expression), indicating the occurrence of mitotic arrest[1].
KMG-732 (0.1 μM; 2-8 h) induces time-dependent G2/M phase arrest in HCT116, Mia-paca2 and BxPC3 cancer cells in vitro[1].
KMG-732 (10 nM; 24 h) significantly inhibits migration and invasion of HCT116 colorectal cancer cells in vitro, reducing both migratory and invasive capacities by over 40%, and this effect occurs without a decrease in cell viability[1].
KMG-732 (0.1-1000 nM; 2 weeks) potently inhibits long-term colony formation of HCT116 colorectal cancer cells in vitro, with complete inhibition achieved at concentrations ≥100 nM[1].
KMG-732 (72 h) maintains potent antiproliferative activity in both parental K562 leukemia cells (GI50 = 20.7 nM) and P-gp-overexpressing K562A leukemia cells (GI50 = 14.8 nM).
KMG-732 (0.002-10 μM) exhibits anti-tumor activity in intestinal tumor organoids derived from Apc^(1638n/+) mice, with an IC50 of 0.021 μM[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:HCT116 colorectal cancer cells
-
Concentration:0.1 μM
-
Incubation Time:1 h
-
Result:Caused complete collapse of organized α- and β-tubulin filament networks, with tubulin aggregating in perinuclear regions.
-
Cell Line:HCT116 colorectal cancer cells
-
Concentration:1 μM
-
Incubation Time:6 h
-
Result:Caused a rapid and significant decrease in levels of acetylated and detyrosinated α-tubulin (markers of stable, polymerized microtubules), while total α-tubulin levels remained unchanged.
-
Cell Line:HCT116, Mia-paca2, and BxPC3 cancer cells
-
Concentration:0.1 μM
-
Incubation Time:0, 2, 4, 6 and 8 h
-
Result:KMG-732 induces rapid, time-dependent accumulation of cells in the G2/M phase across all cell lines tested, with HCT116 cells showing an absolute increase of approximately 25 percentage points in the G2/M population after 8 hours of treatment.
-
Cell Line:HCT116 colorectal cancer cells
-
Concentration:10 nM
-
Incubation Time:24 h
-
Result:Significantly reduces both migration and invasion of HCT116 colorectal cancer cells in Transwell assays, with both capacities inhibited by more than 40%.
-
Cell Line:Drug-resistant K562A (P-gp overexpressing) and parental K562 leukemia cells
-
Concentration:Serial concentrations
-
Incubation Time:72 h
-
Result:Showed comparable antiproliferative activity in parental K562 cells (GI50 = 20.7 nM) and P-gp-overexpressing K562A cells (GI50 = 14.8 nM), whereas colchicine showed a ~85-fold increase in GI50 in K562A cells relative to parental K562 cells.
-
Cell Line:HCT116 colorectal cancer cells
-
Concentration:10 nM
-
Incubation Time:24 h
-
Result:Significantly suppresses the migratory capacity of HCT116 colorectal cancer cells in a wound-healing assay, without affecting cell viability.
Parmacokinetics
| Species | Dose | Route | Tmax | Cmax | T1/2 | AUClast | MRTlast | Bioavailability | CL | Vss |
|---|---|---|---|---|---|---|---|---|---|---|
| Mice[1] | 5 mg/kg | i.v. | / | / | 4.6 h | 1.09 μg·h/mL | 1.39 h | / | 4.72 L/h/kg | 7.91 L/kg |
| Mice[1] | 10 mg/kg | i.p. | 0.08 h | 2.89 μg/mL | 6.54 h | 1.71 μg·h/mL | 0.73 h | 78.6 % | / | / |
| Mice[1] | 10 mg/kg | p.o. | 0.25 h | 0.29 μg/mL | 4.21 h | 0.33 μg·h/mL | 2.73 h | 15.0 % | / | / |
In Vivo
No significant toxicity or mortality is observed in C57BL/6 mice treated with KMG-732 (5-20 mg/kg; i.p.; single administration)[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:athymic BALB/c nu/nu (male, 6 weeks old)[1]
-
Dosage:0.5 mg/kg
-
Administration:i.p.; every other day; 16 days
-
Result:Reduced tumor volume by 67.5% compared to the vehicle-treated group.
Maintained stable body weight throughout the study, with no significant weight loss observed.
-
Animal Model:C57BL/6 (female, 8 weeks old)[1]
-
Dosage:5 mg/kg; 10 mg/kg; 20 mg/kg
-
Administration:i.p.; single dose
-
Result:Maintained stable body weight with no significant weight loss observed over 7 days.
Detected no severe clinical symptoms (e.g., tremors, hypoactivity).
Maintained 100% survival, with survival curves overlapping the vehicle group.
Chemical Information
-
Molecular Weight 391.43
-
Formula C23H17N7
-
SMILES
CN1C=C(C(C2=CC=CC=C2)=N1)C3=C(C(N)=NC(C4=NNC5=C4C=CC=C5)=C3)C#N
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Western Blot
Western blotting (WB) is a commonly used experimental method in molecular biology, biochemistry, and immunogenetics for identifying and quantifying target proteins. It combines gel electrophoresis with immunoassay, enabling researchers to analyze protein expression, post-translational modifications, and molecular weight.
-
Scratch/Wound-Healing Migration Assay
The scratch/wound-healing migration assay measures collective migration of adherent cells into an experimentally created cell-free gap in a confluent monolayer. The readout is generated by imaging the gap immediately after scratching and at later time points, then quantifying reduction in wound area, wound width, or percentage closure as cells move into the denuded region. Gap closure reflects cell migration but may also include cell proliferation, so interpretation should distinguish migration-focused conditions from proliferation-driven closure when possible, such as by using short assay windows, serum-controlled conditions, cell counting, or proliferation controls reported in published protocols.
-
BrdU Incorporation Assay
Bromodeoxyuridine (BrdU) incorporation assay is based on the principle that BrdU, a thymidine analog, is incorporated into newly synthesized DNA during the S phase of the cell cycle, thereby serving as a marker of DNA replication and cellular proliferation. Incorporated BrdU can be detected using anti-BrdU antibodies following DNA denaturation, enabling visualization or quantification of proliferating cells through immunochemical detection methods such as immunofluorescence or immunohistochemistry.
-
Cell migration
Cell migration is a method that plays an important role in wound healing, cell differentiation, embryonic development, etc.
-
Neural Crest/Neuronal Cell Migration Explant Assay
Neural crest (NC) and neuronal cell migration explant assays are in vitro systems in which neural tube-derived tissues are cultured to allow premigratory or newly emigrated neural crest cells to undergo epithelial-to-mesenchymal transition (EMT), migrate away from the explant, and form a measurable radial outgrowth that reflects migratory capacity and environmental responsiveness. These assays typically quantify migration by measuring the expansion of cell outgrowth from neural tube or neural plate border explants over time, often comparing early and later timepoints to derive a migration index such as a radius ratio, which reflects net cell dispersal from the explant core. Neural tube explant cultures preserve key aspects of neural crest behavior, including EMT, migration, and early differentiation, making them suitable for assessing intrinsic migratory ability and extrinsic cue dependence. However, studies emphasize that migratory outgrowth from neural tube explants may include non-n
-
Protocol for Cell Cycle
Cell-cycle analysis by flow cytometry measures DNA content in single cells to estimate the fraction of cells in G0/G1, S, and G2/M phases. Propidium iodide intercalates into DNA, and after RNA removal with RNase, fluorescence intensity reflects cellular DNA content: 2N cells are assigned to G0/G1, cells between 2N and 4N to S phase, and 4N cells to G2/M. DNA-content analysis alone cannot reliably separate G0 from G1 or G2 from M. Ki-67 can distinguish quiescent G0 cells from cycling cells, EdU or BrdU incorporation marks active DNA synthesis in S phase, and phospho-histone H3 staining identifies mitotic cells within the 4N population.
-
Cell Viability Determination by MTT Colorimetric Assay
The following protocol uses the MTT colorimetric assay as a classic literature-established method for assessing cell viability/metabolic activity in cultured mammalian cells. MTT[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] is reduced by metabolically active cells to a colored formazan product; the amount of formazan is quantified spectrophotometrically and provides an indirect measure of metabolically active viable cells. Importantly, MTT reduction reflects cellular oxidoreductase/metabolic activity rather than an absolute direct count of living cells, so changes in cellular metabolism can alter the signal independently of cell number.
-
Kinase activity and phosphorylation assays
Kinase activity assays measure the ability of kinases to transfer phosphate groups from ATP to specific substrates, while phosphorylation assays detect the presence and levels of phosphorylated proteins. Common methods include radiolabeled ATP incorporation (e. g. ,), ADP release detection via bioluminescence (e. g. ,[3]), enzyme-linked immunosorbent assays (ELISA) for phospho-specific epitopes (e. g. ,[6]), and microtiter-based formats for high-throughput screening (e. g. ,[8]). The ADP-Glo assay quantifies kinase activity by measuring ADP produced during phosphorylation using a luciferase-based system. Radiometric assays involve autoradiography or scintillation counting after incorporation of 32P-labeled ATP into substrate proteins. ELISA-based approaches rely on phospho-specific antibodies to detect activated kinases in cell lysates or purified samples.
-
Flow cytometric DNA-content cell-cycle staining
Flow cytometric DNA-content cell-cycle staining measures the fluorescence intensity of DNA-bound fluorochromes in single cells or nuclei to estimate DNA content distributions, allowing assignment of populations to G0/G1, S, and G2/M phases by DNA histogram deconvolution. Propidium iodide (PI) intercalates into DNA, and PI fluorescence is proportional to cellular DNA content when staining is performed under conditions that make DNA accessible and minimize non-DNA signal. Cells with G2/M DNA content are expected to show approximately twice the fluorescence intensity of G0/G1 cells, while S-phase cells occupy intermediate fluorescence values. PI-based DNA-content analysis can also detect cells with fractional DNA content, often reported as sub-G1, when DNA fragmentation and extraction during staining reduce retained DNA signal in apoptotic cells. DAPI is an alternative DNA fluorochrome for univariate DNA-content analysis, while bivariate approaches combining DNA content with proliferation
-
Chemotaxis Gradient Chamber Assay 1
The chemotaxis gradient chamber assay is based on the principle of observing directional cell migration in response to a stable, linear or quasi-linear concentration gradient of a chemoattractant formed between two fluid reservoirs separated by a narrow observation chamber. Cells placed within the chamber respond to the gradient by polarized movement toward higher chemoattractant concentrations, allowing quantification of chemotactic behavior in real time under microscopy. The classic Zigmond chamber design enables simultaneous visualization of gradient formation and individual cell trajectories, making it suitable for studying leukocyte chemotaxis and other motile cell types in vitro.
-
Under-Agarose Cell Migration Assay
The under-agarose cell migration assay is a classical in vitro chemotaxis method designed to evaluate directed cell movement through a semi-solid agarose matrix toward soluble chemoattractant gradients, enabling visualization and quantification of leukocyte or motile cell migration in a confined 2D-like environment. In this system, cells and chemoattractants are placed in separate wells cut into an agarose gel, allowing diffusion-driven gradient formation that guides directional migration, which is typically assessed by measuring migration distance, cell morphology changes, and accumulation toward the chemoattractant source. This assay has been widely used to study neutrophil and leukocyte chemotaxis as a simple alternative to filter-based migration systems and allows direct microscopic observation of migrating cells under near-physiological confinement conditions.
-
Transwell/Boyden Chamber Migration Assay
The Transwell/Boyden chamber migration assay measures cell movement through a porous membrane separating an upper and lower chamber, usually after a chemoattractant gradient is established by placing cells in the upper chamber and chemoattractant-containing medium in the lower chamber. The readout is generated by quantifying cells that traverse the membrane and appear on the lower membrane surface or in the lower chamber, depending on whether the cell type is adherent or non-adherent. This assay reflects chemotactic or haptotactic migration rather than matrix invasion unless an extracellular-matrix barrier is added to the membrane.
-
Patient-Derived Xenograft (PDX)
Patient-derived xenograft (PDX) models are generated by engrafting primary human tumor tissue directly into immunodeficient mice, allowing in vivo propagation of patient tumor biology without initial in vitro adaptation. These models are used to preserve key histopathological and molecular characteristics of the original tumor and enable assessment of tumor growth dynamics and therapeutic response in a living organism. The biological readout is tumor engraftment and subsequent growth in the murine host, which reflects the ability of human tumor cells to survive, vascularize, and expand in an immunocompromised microenvironment.
-
3D Collagen/Hydrogel Matrix Migration Assay
The 3D collagen/hydrogel matrix migration assay is based on embedding cells within or on top of a fibrillar collagen type I-rich three-dimensional matrix to model in vivo-like extracellular matrix (ECM) architecture, enabling analysis of cell migration through a physically and biochemically relevant scaffold. In contrast to 2D migration systems, cells in 3D matrices interact with fibrillar collagen networks, requiring coordinated adhesion remodeling and proteolytic or non-proteolytic deformation mechanisms to move through confined spaces, thereby providing a more physiologically relevant readout of invasive and migratory behavior in tissue-like environments. Cell movement in 3D collagen matrices is typically quantified by tracking single-cell trajectories, invasion depth, or matrix penetration over time, reflecting combined effects of cytoskeletal dynamics, cell-ECM adhesion turnover, and ECM remodeling. These systems are widely used to study tumor cell invasion and stromal cell motili
-
Cell invasion
Cell invasion is the ability of cells to migrate from one area to another via the extracellular matrix. Cell invasion is the response of normal and cancer cells to chemical and mechanical stimuli. Before migrating to a new region, the extracellular matrix is degraded by proteases within the cell. Cell invasion often occurs during wound repair, vascularization and inflammation, abnormal tissue invasion, and tumor cell metastasis.
-
Splenic/Portal-Vein Liver Metastasis Xenograft
Splenic and portal-vein liver metastasis xenograft models deliver tumor cells into the portal circulation so that cells reach the liver first and form hepatic metastatic lesions; splenic injection uses the spleen as an access route to the portal system, while direct portal-vein injection introduces cells into the portal vein without requiring splenectomy. The assay detects liver colonization, intrahepatic tumor growth, tumor distribution, treatment response, survival, and liver-metastasis microenvironment changes; readouts include bioluminescence or fluorescence imaging, gross liver nodule counts, liver weight or tumor burden, histology, and survival.
-
Protocol for Kinase activity and phosphorylation assays
Kinase activity assays measure transfer of phosphate from ATP to a protein or peptide substrate, generating phosphorylated substrate, ADP, or incorporated radiolabeled phosphate as the readout; phosphorylation assays measure site-specific phosphorylation in cells or tissues as a proxy for kinase-pathway activation, inhibition, or substrate regulation. Phosphorylation can be detected by phospho-specific Western blot, immunoprecipitation kinase assay, phospho-immunofluorescence, phospho-flow cytometry, luminescent ADP detection, radiolabeled ATP incorporation, or reporter-based pathway assays, and these readouts can be applied to cancer cells, primary neurons, mouse tumors, organoids, inflammatory macrophages, ferroptosis studies, and mitophagy studies when the kinase target is biologically relevant.
-
Subcutaneous Cell-Line-Derived Xenograft
Subcutaneous cell-line-derived xenograft (CDX) models are established by implanting cultured human cancer cell lines into immunodeficient mice, where the injected cells form localized tumors that can be monitored in vivo as a measure of tumorigenic potential, growth kinetics, and treatment response. These models are widely used in oncology research because they allow reproducible tumor formation and enable comparative assessment of tumor growth between different cell lines or genetic manipulations in a controlled in vivo microenvironment. Subcutaneous implantation of cancer cells in immunodeficient mice is a standard approach for evaluating tumor growth behavior and therapeutic response across multiple cancer types, including prostate, esophageal, pancreatic, and colon cancer models.
-
Cell-Exclusion Zone Migration Assay
The Cell-Exclusion Zone (CEZ) migration assay is an in vitro 2D cell migration method in which a defined cell-free area is created using removable physical barriers such as silicone stoppers, allowing cells to be seeded around the barrier and subsequently migrate into the cleared zone after barrier removal. This approach enables quantification of collective cell migration by monitoring repopulation of the initially cell-free region over time using microscopy-based imaging. Compared with scratch-based wound healing assays, barrier-based exclusion methods are designed to avoid mechanical damage to the extracellular matrix and reduce injury-induced effects on boundary cells, thereby improving interpretability of migration behavior in vitro. The assay readout is typically the progressive reduction in the cell-free area or the number of cells invading the exclusion zone, reflecting coordinated cell motility relevant to physiological processes such as wound healing, epithelial repair, and ca
-
Chemotaxis Gradient Chamber Assay 2
Chemotaxis gradient chamber assays measure directional cell migration in response to a soluble chemical gradient by imaging cells as they move across a defined observation region; the readout is generated from time-lapse cell trajectories, displacement toward the gradient, forward migration index, trajectory plots, rose/polar plots, and statistical tests of non-random directionality. The Dunn chamber is a direct-viewing glass chamber in which cells migrate across a bridge between control and chemoattractant wells, allowing observation of cells in a linear concentration gradient; related direct-viewing formats include the Insall chamber, which supports defined unidirectional gradients and high numerical-aperture microscopy, and the μ-Slide Chemotaxis chamber, which supports long-term live-cell imaging and gradient characterization with fluorescent dye.
-
Orthotopic Cell-Line Xenograft
Orthotopic cell-line xenograft models involve implantation of human cancer cell lines into the anatomically corresponding organ of immunodeficient mice to reproduce tumor growth within a native microenvironment, enabling more clinically relevant tumor behavior compared with subcutaneous models. These models are widely used because orthotopic placement better recapitulates tumor progression, including invasion and metastatic spread, which are often underrepresented in heterotopic implantation systems. Compared with conventional xenografts, orthotopic implantation is described as more technically complex but provides improved simulation of tumor-microenvironment interactions and metastatic behavior, making it particularly valuable for translational oncology research. Surgical orthotopic implantation approaches have been emphasized as enabling faithful reproduction of clinical cancer features, including metastasis and disease progression patterns that align with the tumor’s organ of origi
-
Intraperitoneal/Peritoneal Dissemination Xenograft
Intraperitoneal (IP) or peritoneal dissemination xenograft models are based on the introduction of human cancer cells into the peritoneal cavity of immunodeficient mice, where they attach to peritoneal surfaces, form multicellular aggregates or spheroids, and progressively generate disseminated tumor nodules that mimic advanced peritoneal metastatic disease. These models are widely used to study ovarian cancer progression, tumor-microenvironment interactions, and intraperitoneal therapeutic responses, often incorporating bioluminescence or fluorescence imaging to longitudinally monitor tumor burden in vivo. The biological principle relies on the capacity of tumor cells such as SKOV3 or related ovarian carcinoma lines to survive in suspension, aggregate within ascites-like fluid, adhere to mesothelial surfaces, and invade peritoneal organs, thereby recapitulating human peritoneal carcinomatosis patterns observed in advanced disease.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)